Phospho-CLDN5 (Tyr217) Antibody

What is Phospho-CLDN5 (Tyr217) Antibody and why is it important in neuroscience research?

Phospho-CLDN5 (Tyr217) Antibody is a research tool that specifically detects endogenous levels of Claudin-5 protein only when phosphorylated at tyrosine 217. Claudin-5 is a crucial tight junction protein that plays a central role in regulating the permeability of endothelial barriers, particularly in the formation and maintenance of the blood-brain barrier (BBB) .

The importance of this antibody stems from its ability to monitor post-translational modifications that directly affect BBB integrity. Research has shown that phosphorylation of Claudin-5 at Tyr217 is associated with diminished barrier tightness and enhanced monocyte migration across the BBB in pathological conditions like HIV-1 encephalitis . This makes the antibody an invaluable tool for studying BBB dysfunction in various neurological disorders.

For long-term storage, manufacturers consistently recommend storing the antibody at -20°C for up to one year from the date of receipt . For frequent use and short-term storage (up to one month), 4°C is acceptable . It's crucial to avoid repeated freeze-thaw cycles as this can degrade antibody quality and performance .

The antibody is typically provided in liquid form with the following formulation:

• PBS (without Mg²⁺ and Ca²⁺, pH 7.4)

• 50% glycerol

• 0.02% sodium azide

• Sometimes includes 0.5% BSA

When preparing working dilutions, it's advisable to make fresh solutions and use them within the same day for optimal binding activity.

What is the molecular mechanism of Claudin-5 phosphorylation at Tyr217 and its impact on blood-brain barrier integrity?

The phosphorylation of Claudin-5 at Tyr217 occurs within the C-terminal region (amino acids 169-218) and significantly impacts tight junction stability and blood-brain barrier function. Research has demonstrated that Rho kinase (RhoK) can directly phosphorylate Claudin-5, although at a different site (T207) .

The mechanistic impact of Tyr217 phosphorylation includes:

• Disruption of the interaction between Claudin-5 and ZO-1: The C-terminus of Claudin-5 contains a YV-motif that binds to the N-terminal PDZ domain (PDZ1) of ZO-1. Phosphorylation at Tyr217 interferes with this interaction, leading to attenuated junctional localization of Claudin-5 .

• Altered junctional stability: Phosphorylation-induced changes in Claudin-5 localization affect the structural integrity of tight junctions, which increases paracellular permeability .

• Regulatory pathway involvement: Phosphorylation at Tyr217 is connected to RhoA/Rac1 signaling balance. VE-cadherin, JAM-A, and ZO-1 control the junctional localization of Claudin-5 via this balance, and phosphorylation events can disrupt this control .

Mass spectrometry studies have confirmed the presence of this phosphorylation site in vivo, with enhanced phosphorylation observed in pathological conditions associated with BBB dysfunction .

How can I optimize Phospho-CLDN5 (Tyr217) Antibody detection in different experimental models?

Optimizing Phospho-CLDN5 (Tyr217) Antibody detection requires careful consideration of model-specific factors:

For in vitro cell culture models:

• Cell selection: Human brain microvascular endothelial cells (hCMEC/D3) have been successfully used to study Claudin-5 phosphorylation . For heterologous expression, COS-7 cells transfected with Claudin-5 have been effective .

• Membrane protein isolation: Since Claudin-5 is a tight junction membrane protein, use specialized membrane protein isolation kits to enhance detection sensitivity . Standard RIPA buffer with protease and phosphatase inhibitors is essential for preservation of phosphorylation .

• Positive controls: Include samples treated with phosphatase inhibitors to preserve phosphorylation status. Some studies utilize RhoK inhibitors (like Y27632) as negative controls to validate phosphorylation specificity .

For tissue analysis:

• Fixation protocols: For IHC/IF in tissues, optimal fixation is critical. 4% PFA (paraformaldehyde) fixation is commonly used, with careful attention to fixation time to preserve epitope accessibility .

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) can enhance antibody binding to the phosphorylated epitope in formalin-fixed tissues .

• Visualization methods: For difficult-to-detect signals, tyramide signal amplification or high-sensitivity detection systems may improve results in tissue sections .

What are the known pathological conditions associated with altered Claudin-5 phosphorylation at Tyr217?

Research has identified several pathological conditions where Claudin-5 phosphorylation at Tyr217 is implicated:

• HIV-1 Encephalitis: Enhanced phosphorylation of Claudin-5 has been observed in both human and mouse models of HIV-1 encephalitis, correlating with mononuclear cell infiltration across a disrupted BBB .

• Schizophrenia: The CLDN5 gene is located within the 22q11.2 deletion syndrome region associated with schizophrenia. While the specific Tyr217 phosphorylation hasn't been directly studied in all cases, altered PKA signaling affecting Claudin-5 phosphorylation (at other sites) has been reported in schizophrenic prefrontal cortex .

• Cancer Metastasis: Studies involving lung cancer brain metastasis models demonstrate that altered Claudin-5 phosphorylation status correlates with brain endothelial cell migration and BBB permeability changes .

• Inflammatory Conditions: Histamine-induced vascular leakage shows tissue-specific differences that correlate with Claudin-5 expression and potential phosphorylation state changes .

Interestingly, the phosphorylation dynamics differ between acute and chronic conditions, suggesting time-dependent regulatory mechanisms worth investigating with time-course studies using the Phospho-CLDN5 (Tyr217) antibody.

How can I design experimental controls to validate Phospho-CLDN5 (Tyr217) Antibody specificity?

Rigorous validation of phospho-specific antibodies requires multiple complementary approaches:

• Phosphatase treatment controls:

  • Split your protein sample and treat half with lambda phosphatase

  • The signal should disappear in the phosphatase-treated sample when probed with Phospho-CLDN5 (Tyr217) antibody

  • A total Claudin-5 antibody should detect both samples equally

• Peptide competition assays:

  • Pre-incubate the antibody with excess phosphorylated and non-phosphorylated peptides

  • The phosphorylated peptide should abolish signal while the non-phosphorylated shouldn't

  • This test has been documented in IHC applications for Phospho-CLDN5 (Tyr217) antibody

• Expression system validation:

  • Create a Y217F mutant (tyrosine to phenylalanine) of Claudin-5 that cannot be phosphorylated

  • Express wild-type and Y217F mutant in appropriate cells

  • The antibody should detect only the wild-type protein under conditions promoting phosphorylation

• Phosphorylation induction:

  • Treat cells with compounds known to induce tyrosine phosphorylation (e.g., pervanadate)

  • Compare with untreated controls to confirm increased signal with the phospho-specific antibody

• Orthogonal detection methods:

  • Confirm phosphorylation at Y217 using mass spectrometry

  • Previous studies have used LC/MS/MS to identify and confirm phosphorylation sites on Claudin-5

What are the methodological considerations for quantifying Claudin-5 phosphorylation levels in different experimental contexts?

Quantifying Claudin-5 phosphorylation requires attention to several methodological details:

For Western blot quantification:

• Normalization strategy: Always normalize phospho-Claudin-5 signal to total Claudin-5 protein rather than housekeeping proteins. This accounts for variations in total Claudin-5 expression between samples .

• Membrane preparation: Since Claudin-5 is a tight junction protein, specialized membrane protein isolation improves quantification accuracy. Standard protocols may lead to inconsistent extraction efficiency .

• Denaturation conditions: Use optimal denaturation conditions (95°C for 5 minutes in Laemmli buffer) to ensure complete protein denaturation without affecting phospho-epitopes .

For immunohistochemical/immunofluorescence quantification:

• Co-localization analysis: Co-stain with endothelial markers (e.g., CD31) and tight junction proteins (e.g., ZO-1) to specifically assess junctional phosphorylation versus internalized protein .

• Signal intensity measurement: Use digital image analysis software with background subtraction and uniform threshold settings across all comparative samples .

• Confounding factors: Account for vascular density variations between samples by normalizing phospho-signal to vessel area or length .

For in vivo studies:

• Regional variability: Different brain regions display varying Claudin-5 expression levels and phosphorylation states. The cerebral cortex, hippocampus, and cerebellum should be analyzed separately .

• Experimental timing: Phosphorylation is a dynamic process - careful consideration of the time point for analysis is critical, especially in acute challenge models (e.g., post-ischemia, post-inflammatory challenge) .

• Transgenic models: Compare with Claudin-5 knockout or knock-in models (such as Cldn5flox/flox mice crossed with Cdh5(PAC)-CreERT2) to establish baseline and validate antibody specificity .

How can I effectively use Phospho-CLDN5 (Tyr217) Antibody in blood-brain barrier disruption studies?

When investigating BBB disruption, Phospho-CLDN5 (Tyr217) Antibody serves as a valuable molecular marker. Here's a methodological approach:

• Establish baseline phosphorylation: Determine normal phosphorylation levels in your model system using healthy controls. This is essential as basal phosphorylation varies between vascular beds and animal models .

• Correlate with functional BBB assessments: Combine antibody detection with permeability assays using molecular tracers (e.g., Evans blue, fluorescent dextrans of various molecular weights) . Research has demonstrated that phosphorylation at Y217 correlates with increased permeability to molecules under 800 Da .

• Experimental design approaches:

  • Acute vs. chronic models: For acute BBB disruption (e.g., inflammatory challenges), collect samples at multiple time points (1h, 3h, 6h, 24h) to capture dynamic phosphorylation changes

  • Pharmacological interventions: Use specific kinase inhibitors to modulate phosphorylation and correlate with BBB integrity

  • Genetic approaches: Utilize CLDN5 mutant constructs (phospho-mimetic Y217E or phospho-deficient Y217F) to study functional consequences

• Multiplex analysis: Combine Phospho-CLDN5 (Tyr217) Antibody with other tight junction markers (occludin, ZO-1) and signaling pathway components (RhoA/Rac1) for comprehensive pathway analysis .

A published experimental workflow that has proven effective includes tissue preservation with rapid fixation, careful antigen retrieval, and analysis focusing on vessel-rich regions with consistent morphology between samples .

What is the relationship between Claudin-5 phosphorylation at Tyr217 and other post-translational modifications of tight junction proteins?

Tight junction regulation involves complex interplay between multiple post-translational modifications. For Claudin-5, phosphorylation at Y217 exists within a network of modifications:

• Coordinated phosphorylation events:

  • Research has identified multiple phosphorylation sites on Claudin-5, including T207 (by RhoK)

  • Y217 phosphorylation appears to precede certain changes in T207 phosphorylation status in some models

  • Studies suggest potential "phosphorylation codes" where specific combinations of phosphorylated residues dictate barrier properties

• Cross-talk with other tight junction proteins:

  • Occludin phosphorylation (at T382 and S507) often occurs concurrently with Claudin-5 phosphorylation in BBB disruption models

  • This suggests coordinated regulation through shared kinase/phosphatase networks

• Relationship with other modifications:

  • Palmitoylation of Claudin-5 at cysteine residues affects its membrane localization and may influence accessibility to kinases that phosphorylate Y217

  • Ubiquitination pathways can be activated following phosphorylation, leading to Claudin-5 degradation in some pathological conditions

• Functional consequences of coordinated modifications:

  • Phosphorylation at Y217 appears to affect protein-protein interactions with scaffold proteins like ZO-1

  • This in turn alters the stability of the multiprotein tight junction complex

Understanding these interrelationships is crucial when designing experiments to study BBB dysfunction using Phospho-CLDN5 (Tyr217) Antibody, as multiple pathways may need to be inhibited simultaneously to observe functional effects.

What are the recommended protocols for using Phospho-CLDN5 (Tyr217) Antibody in different experimental techniques?

Below are optimized protocols based on published research and manufacturer recommendations:

For Western Blot:

• Sample preparation:

  • For cell lysates: Use Minute™ Plasma Membrane Protein Isolation Kit or equivalent for tight junction protein enrichment

  • For tissue: Homogenize in RIPA buffer containing protease and phosphatase inhibitors (critical for preserving phosphorylation)

  • Protein quantification: BCA assay followed by normalization to equal concentrations

• Electrophoresis and transfer:

  • Load 50μg protein per lane on 12% SDS-PAGE gel

  • Transfer to PVDF membrane at 100V for 90 minutes in cold transfer buffer

• Antibody incubation:

  • Block with 5% non-fat milk in PBST for 1 hour at room temperature

  • Primary antibody: Dilute Phospho-CLDN5 (Tyr217) Antibody at 1:500-1:1000 in 5% BSA/TBST

  • Incubate overnight at 4°C with gentle agitation

  • Secondary antibody: Anti-rabbit HRP at 1:5000-1:10000 for 1 hour at room temperature

• Detection:

  • ECL substrate with exposure optimized for signal intensity

  • Expected band: ~23 kDa

For Immunohistochemistry:

• Tissue preparation:

  • Fix tissues in 4% PFA (paraformaldehyde) for 24 hours

  • Paraffin embedding and section at 5-10μm thickness

• Staining protocol:

  • Deparaffinize and rehydrate sections

  • Antigen retrieval: Citrate buffer (pH 6.0) at 95°C for 20 minutes

  • Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

  • Block non-specific binding with 5% normal goat serum for 1 hour

  • Primary antibody: Dilute at 1:50-1:100 and incubate overnight at 4°C

  • Detection: HRP-polymer system followed by DAB development

  • Counterstain: Hematoxylin for nuclear visualization

• Positive control:

  • Human brain tissue is recommended as a positive control

  • Include phosphopeptide blocking controls to demonstrate specificity

How can I investigate the relationship between Claudin-5 phosphorylation state and gene expression in disease models?

Investigating the relationship between Claudin-5 phosphorylation and gene expression requires integrated approaches:

• Temporal analysis design:

  • Establish time course experiments examining both phosphorylation status (using Phospho-CLDN5 (Tyr217) Antibody) and mRNA expression

  • Research has revealed important discrepancies between mRNA and protein levels of Claudin-5 in schizophrenia models

  • Document both acute (0-24h) and chronic (days-weeks) changes in different model systems

• Pathway investigation:

  • cAMP signaling induces CLDN5 mRNA expression in a PKA-independent manner while promoting Claudin-5 phosphorylation in a PKA-dependent fashion

  • Design experiments that selectively inhibit different components of these pathways to delineate effects on phosphorylation versus transcription

• Methodological approaches:

  • Combine Western blotting for phosphorylation state with qRT-PCR for mRNA quantification

  • Consider using RNAscope Fluorescent Multiplex Assay to visualize CLDN5 mRNA in combination with Phospho-CLDN5 immunostaining to assess correlation at single-cell resolution

  • Single-cell or nucleus RNA sequencing can reveal cell-type specific expression patterns of CLDN5 across tissues

• Transcriptional regulation analysis:

  • Examine key transcriptional factors for ECs (ERG, ETS-1, SOX-18, KLF-4) that bind to the CLDN5 promoter

  • Investigate how phosphorylation state might influence these transcriptional networks through feedback mechanisms

This integrated approach can help clarify whether phosphorylation state affects gene expression through feedback mechanisms or if they are independently regulated processes in specific disease contexts.

What are common troubleshooting issues when using Phospho-CLDN5 (Tyr217) Antibody and how can I resolve them?

For tissue-specific optimization, published work indicates that human brain tissue requires careful antigen retrieval and longer primary antibody incubation (overnight at 4°C) for optimal results .

How can I distinguish between specific and non-specific signals when using Phospho-CLDN5 (Tyr217) Antibody?

Distinguishing specific from non-specific signals requires systematic validation:

• Essential controls:

  • Peptide competition: Pre-incubate antibody with phosphorylated peptide to block specific binding. Signal should disappear in IHC or Western blot

  • Phosphatase treatment: Treat half of your sample with lambda phosphatase. Phospho-specific signal should be eliminated while total Claudin-5 remains detectable

• Genetic controls:

  • Use tissue/cells from Claudin-5 knockout models as negative controls when available

  • Alternatively, use siRNA knockdown of CLDN5 in cell culture to reduce specific signal

• Pattern recognition:

  • Authentic Phospho-CLDN5 staining should localize to cell junctions in endothelial cells

  • In Western blots, the specific band should appear at approximately 23 kDa

• Cross-validation:

  • Use multiple antibodies targeting different epitopes of Claudin-5

  • Confirm phosphorylation events with mass spectrometry when possible

• Positive control tissues:

  • Human brain endothelial cells in HIV-1 encephalitis show enhanced phosphorylation

  • Mouse models with RhoK activation typically display increased phosphorylation